Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
though it was not a good deal with reverse split for zlcs share holders. with newly listed epirus the products they have in pipeline especially BOW015 complete approved in India has a huge market with no competitors. I am very positive it may shoot up nicely tomorrow.... I am still holding... good luck to all longs and those who are holding for tomorrow...
I wish that could hapen and good bump to opening price.... waiting for tomorrow if we see any pr at all.... I am kind of down at this time as I bought with avg of 1.42
I WONDER WHAT NEWS NEW COMPANY HAS TO PR I BET THERES ALOT OF VERY GOOD NEWS
open up tomorrow should be strong... let's see tomorrow how it trades...
Confused on why not higher. $1.16 and will reverse split in the am.1-10. With 26 million shares outstanding drops to 2.6 million and $12 million in cash from ZLCS.
$12 stock with $4 plus in cash and whatever EPRS brings to table. When the new company financials are public then we will see some fireworks. Up I hope.
I know we are only to 19% of new com[any but no mention of that. Just the 1 for 10 reverse.
Tomorrow will be exciting... and more to come this week... go merger with epirus $$$
Yes.. just one more week to go.... people will regret when they have to run after it....
At a $1.16 ZLCS and the new merged company Epirus bio is valued at $160 million. ZLCS brings $12 million cash and a potential larger amount in future. The new Company brings an approved Billion dollar RA drug in India, recent $35 million and much more.
Folks this is a steal.Do your own DD and you will say WOW...I want in!
Absolutely, it will shootup easily to $3 in next 2 weeks... if we can wait till end of july we will be rewarded with lot more than expected under epirus listing... gl..
8 more trading days. $3 plus possible.
this stock should be moving up in2-3 weeks
ZLCS will bring an estimated $9-12 million to the merged company and a potential 17 million with residuals. Epirus has received $36 million in financing in april 2014. Combined with exciting drug approved in India and we should see quite a run once the financials are released as a new company. Money in the bank from $1.26 way too cheap.
RA drug used to help alopecia patients grow hair was reported today. Epirus may have that in their RA drug. Could be a unexpected boom to their already approved RA drug in india.
http://www.dailymail.co.uk/news/article-2663086/Yale-scientists-successfully-use-arthritis-drug-regrow-completely-bald-mans-hair.html
I dont have private message. Thank you for your good wishes and i say glty too. Hold for a moment this is going to blow.
Got in today. Expect good revenues for 2014 !!!
This is really a good news of $17 mil revenue, half of its current cap....I am wondering why the price is not moving up... I am still holding, let's see how it goes in last 2 hours...
ask me if they do not understand the NEWS
Interesting article I found pertaining to new drug http://beforeitsnews.com/health/2014/01/global-rheumatoid-arthritis-disease-market-2018-forecast-analysis-in-new-research-report-2520864.html
Hum are you new to trading you seem a lil hesitant no pun intended
I heard when merger is complete the new company could start off at 3.50 share anyone else here this?
Here is some info regarding the merger:
http://www.businesswire.com/news/home/20140416005356/en/Epirus-Zalicus-Announce-Merger-Agreement#.U55bRXi9LCQ
You can check out info on the Epirus pipeline here:
http://www.epirusbiopharma.com/development-pipeline/overview.php
What is ZLCS worth to the merger party?
What's the pipeline valued at and why are
They merger?
Thanks!
I agree I saw SPEX at these levels before it spiked up to $4.20 range huge profits
This could be a multi bagger with good news IMO. The merger will be interesting.
Made a small gain here got out with a lol profit taking but that's just how they play the game might get back in with these good looking prices can stay down at these levels too much long :) I'll see if the 10daySMA holds might jump in for the long haul GLTA
Oh,yeah.. I don't think any shareholder will disagree with this after the Epirus phase 3 results.. Looks like we may have to hold our shares till end of July if we don't see any highs before that....
8k said merger will take place over the summer
I am wondering why they are not releasing a pr... holding big and worried if merger doesn't happen...
clear buy signal
Weird, still haven't hear back after three emails sent lol. Ridiculous
ANY ONE KNOW WHY NO PR OR TALKED TO CO.OR GET E-MAIL FROM CO.
advertising is always good
Finally joining forces with Beambe haha. On ZLCS and AMCO.
Of a PR comes out confirming the data from Phase III and confirming the company is moving forward with the planned and scheduled merger, who knows how high it can go. Look at the volume here 11 million, our float is tiny and considering the bulk of the volume and shares we're bought higher today, should spike up nice in my opinion
Before always buy low sell high
Oh man not saying a peep lol. Don't want to be held to anything haha
I'm loaded as can be
should I invest before or after the NEWS
UP we go. $1.5++++. Zalicus- ZLCS
I'm think the co may issue a press release after the close today with more details
Epirus Biopharmaceuticals announced positive data from a Phase 3 trial of BOW015 in patients with active rheumatoid arthritis; ZLCS entered into an agreement and plan of merger with Epirus
Lunch time over let's get this thing back up. Looking for an official PR from the company.
Loaded up these cheapies hopefully we close nicely
Followers
|
75
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
2191
|
Created
|
08/12/07
|
Type
|
Free
|
Moderators |
http://finance.yahoo.com/q/ks?s=ZLCS
http://www.form4oracle.com/company?cik=0001135906&ticker=crxx
Zalicus Inc., a biopharmaceutical company, engages in the development of drug candidates focusing on the treatment of pain and inflammation. The company's clinical and preclinical product candidates for pain, inflammation, and other central nervous system disorders include Synavive (CRx-102), a novel dissociated glucocorticoid product candidate, which has completed Phase II clinical trials in subjects with knee osteoarthritis, to treat immuno-inflammatory disorders; Prednisporin (FOV1101), a topical ophthalmic drug candidate containing low doses of the glucocorticoid prednisolone acetate and the immunosuppressant cyclosporine A; N-type and T-type calcium channel blockers for the treatment of chronic pain; and CRx-601, a formulation of carbidopa and levodopa for the treatment of Parkinson's disease. It is also developing CRx-401 for Type 2 diabetes; CRx-191 and CRx-197 for psoriasis. It has a research collaboration and license agreement with the Novartis Institutes of Biomedical Research; a collaboration agreement with PGxHealth, LLC for the development of ATL313, an adenosine A2A receptor agonist compound owned by PGxHealth; collaboration agreement with Mallinckrodt Inc., Fovea Pharmaceuticals SA, and National Institutes of Allergy and Infectious Diseases; and a cooperative research and development agreement with the United States Army Medical Research Institute for Infectious Diseases. The company was formerly known as CombinatoRx, Incorporated and changed its name to Zalicus Inc. on September 9, 2010. Zalicus Inc. was founded in 2000 and is based in Cambridge, Massachusetts.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |